Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $117 | In Stock | |
5 mg | $289 | In Stock | |
10 mg | $455 | In Stock | |
25 mg | $889 | In Stock | |
50 mg | $1,360 | In Stock | |
100 mg | $1,860 | In Stock | |
1 mL x 10 mM (in DMSO) | $318 | In Stock |
Description | CCB02 is a selective CPAP-tubulin interaction inhibitor (IC50: 689 nM) with anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora-A, CDK2, Plk1, Plk2, and CHK1. |
In vitro | CCB02 perturbs CPAP PN2-3-tubulin interaction with an IC50 of 0.441 μM in a PN2-3 CPAP-GST pull-down assay. CCB02 (0.1-15 μM, 72 hours) inhibits the proliferation of cancer cells with extra centrosomes (IC50s: 0.86-2.9 μM). CCB02 activates spindle assembly checkpoint, induces PCM proteins recruitment to centrosomes, and enhances microtubule nucleation activities of centrosomes[1]. |
In vivo | CCB02 (30 mg/kg, p.o. daily for 24 days) shows potent anti-tumor effect in nude mice bearing subcutaneous human lung (H1975 T790M cells) tumor xenografts. In mouse xenografts, CCB02 also suppresses MDA-MB-231 cell migration and causes multipolar mitosis[1]. |
Molecular Weight | 235.24 |
Formula | C14H9N3O |
Cas No. | 2100864-57-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 22.5 mg/mL (95.6 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.